Clinical Trial

A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)

Study acronym: FUMANBA-03
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a multicenter, randomized, controlled, open-label, phase III clinical study to evaluate the efficacy of Equecabtagene Autoleucel Injection versus standard therapy in subjects with lenalidomid-refractory RRMM who have received 1-2 lines of prior therapy.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-06-17; most recent amendment 2025-07-16.
Trial Details
NCT Number NCT06464991
Lead Sponsor Nanjing IASO Biotechnology Co., Ltd.
Conditions Multiple Myeloma
Enrollment 240 participants
Start Date 2024-03-27
Primary Completion 2027-08 (estimated)
Study Completion 2030-12 (estimated)
Updated on ClinicalTrials.gov 2025-07-20